TABLE 3.
False-positive HPV types detected by assay typea
| HPV assay type (manufacturer) | No. of data sets | HPV region(s) targeted (primers) | No. of data sets with indicated no. false-positive samples |
||||
|---|---|---|---|---|---|---|---|
| 0 samples | 1 sample | 2 samples | 3 samples | >3 samples | |||
| Linear Array (Roche)b | 18 | L1 (PGMY) | 12 | 2 | 2 | 0 | 2 |
| In-house Luminex PCRc | 11 | E6, E7, L1 | 7 | 2 | 2 | 0 | 0 |
| PapilloCheck (Greiner) | 9 | E1 | 9 | 0 | 0 | 0 | 0 |
| INNO-LiPA (Innogenetics) | 8 | L1 (SPF10) | 1 | 1 | 1 | 1 | 4 |
| In-house line blotd | 8 | E6, E7, L1 | 4 | 2 | 1 | 0 | 1 |
| In-house PGMY-CHUVb | 8 | L1 (PGMY) | 5 | 2 | 0 | 0 | 1 |
| In-house real-time PCRe | 7 | L1/E1/E4/E6/E7 | 6 | 0 | 1 | 0 | 0 |
| In-house type-specific PCRf | 7 | L1/L2/E1/E5/E6/E7/URR | 3 | 1 | 2 | 1 | 0 |
| CLART HPV 2/3 (Genomica)b | 6 | L1 (PGMY) | 3 | 1 | 1 | 0 | 1 |
| Hybribio 21 HPV GenoArray | 5 | L1 (PGMY) | 4 | 1 | 0 | 0 | 0 |
| Cobas 4800 (Roche)g | 4 | L1 | 4 | 0 | 0 | 0 | 0 |
| In-house PCR-EIAh | 4 | L1/E6/E7 | 3 | 0 | 0 | 0 | 1 |
| In-house PCR-RFLPi | 3 | L1/E6/E7 | 2 | 0 | 1 | 0 | 0 |
| In-house pyrosequencingj | 3 | L1 (GP/PGMY) | 2 | 0 | 0 | 0 | 1 |
| Hybribio 14 HRk | 3 | E6/E7 | 3 | 0 | 0 | 0 | 0 |
| PCR Luminex (Multimetrix) | 2 | L1 (GP) | 1 | 1 | 0 | 0 | 0 |
| In-house microarray chipb | 2 | L1 (My/GPM) | 1 | 0 | 0 | 1 | 0 |
| PANArray | 2 | L1 (GP) | 2 | 0 | 0 | 0 | 0 |
| Digene HPV genotyping RH test (Qiagen)k | 2 | L1 (GP) | 1 | 0 | 0 | 0 | 1 |
| Hybribio 13 HRl | 2 | E6/E7 | 2 | 0 | 0 | 0 | 0 |
| HPV Direct-Flow chip (Master Diagnóstica) | 2 | L1 (GP) | 2 | 0 | 0 | 0 | 0 |
| SPF(10)-LiPA25 version 1 (Labo Biomedical Products) | 2 | L1 (SPF10) | 1 | 0 | 0 | 0 | 1 |
| LCD array (Chipron)b | 2 | L1 (PGMY) | 0 | 2 | 0 | 0 | 0 |
| Other commercial assaysm | 10 | L1/E1/E2/E6/E7 | 4 | 2 | 1 | 0 | 3 |
| Other in-house assaysn | 4 | L1/E1/E7 | 2 | 0 | 1 | 0 | 1 |
| All assays | 134 | L1/L2/E1/E2/E4/E5/E6/E7/URR | 84 | 17 | 13 | 3 | 17 |
Unless otherwise stated, all assays test for 17 HPV types.
These assays, using PGMY-based primers, do not test for HPV68a.
Four assays do not test for HPV68a, and one of these does not test for HPV6 and HPV11.
One assay types 9 different HPV types, and one assay types 8 different HPV types.
One assay does not type HPV6 and HPV11, two assays do not type HPV66 and HPV68, one assay types HPV16 and HPV18 only, one assay types HPV52, and one assay types HPV68.
Two assays do not type HPV 66, one assay does not type HPV66 and HPV68, and one assay types HPV16 and HPV18 only.
These assays type HPV16 and HPV18, and the other 12 high-risk types are reported as “other high risk.”
One assay does not type HPV68a, one does not type HPV45, -51, -59, and -68a, and one assay types HPV16 and HPV18 only.
This assay, using PGMY-based primers, does not test for HPV68a; in addition, one assay does not type HPV51.
This assay, using PGMY-based primers, does not test for HPV68a, one assay types 12 different HPV types, and one assay types 8 different HPV types.
This assay does not test for HPV6 or HPV11.
This assay tests for 13 high-risk types, which are reported as positive or negative.
Other commercial assays include one laboratory using each of GenoFlow HPV array kit, Sacace high-risk screen real-TM, AdvenSure HPV GenoBlot assay, BMT HPV Genotyping 9G, Molgentix F-HPV typing assay, ProDect CHIP HPV typing assay, PapType assay, genomed-biotech f-HPV typing assay, Analitica type-specific PCR, and the SPF(10)-LiPA25 version 1 (Labo Biomedical Products).
Other in-house assays include one laboratory using each of in-house PCR, in-house multiplex PCR, in-house hybridization-chemiluminescence, PCR-Sequencing My-GP, and FAP.